Search results for "Vaccinations"
More clarity on myocarditis with mRNA COVID-19 vaccines
The classic presentation for COVID-19 vaccine-associated myocarditis is chest pain one to seven days after vaccination, with a median time of three days after vaccination, particularly after the second dose.
https://immattersacp.org/archives/2023/02/more-clarity-on-myocarditis-with-mrna-covid-19-vaccines.htm
1 Feb 2023
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023
Postexposure prophylaxis drug, vaccine complications, and anticoagulation in COVID-19
A monoclonal antibody combination was effective for postexposure prophylaxis and received emergency use authorization. A study investigated postvaccine myocarditis and pericarditis, and effects of full-dose anticoagulation differed by whether patients were critically ill.
https://immattersacp.org/weekly/archives/2021/08/10/1.htm
10 Aug 2021
Physicians as patients with COVID-19
Physicians who contracted COVID-19 share their perspectives on how the disease has changed their personal and professional lives.
https://immattersacp.org/archives/2022/01/physicians-as-patients-with-covid-19.htm
1 Jan 2022
CDC recommendations on COVID-19 vaccine boosters, new data on vaccine effectiveness
Several groups in the U.S. are now eligible to receive a booster dose of the Pfizer-BioNTech COVID-19 vaccine at least six months after completing the initial two-dose series.
https://immattersacp.org/weekly/archives/2021/09/28/1.htm
28 Sep 2021
COVID-19 research focused on anticoagulation, vaccine-induced thrombocytopenia
Two new studies support prophylactic, rather than therapeutic, anticoagulation for COVID-19 patients, and case reports provide more information about vaccine-induced immune thrombotic thrombocytopenia.
https://immattersacp.org/weekly/archives/2021/06/15/1.htm
15 Jun 2021
Cervical cancer screening may be able to occur later, less often in HPV-vaccinated women, study suggests
When compared with no intervention, vaccination alone with no screening produced a 64.6% mean reduction in lifetime cervical cancer risk, and screening strategies increased this risk reduction to a range of 88% to 98%. The lowest cost-effectiveness ratio was seen with cytology-only screening every 5 years starting at age 35, compared with vaccination alone.
https://immattersacp.org/weekly/archives/2016/10/25/4.htm
25 Oct 2016
Monkeypox: 5 key points
An expert panel convened by ACP and Annals of Internal Medicine provided five key takeaways about diagnosing and managing monkeypox.
https://immattersacp.org/archives/2022/11/monkeypox-5-key-points.htm
1 Nov 2022
New research adds to data on symptoms after COVID-19, vaccines' effects
Several COVID-19 studies looked at persistent symptoms, while new vaccine research found limited antibody responses in some patients and advised on tests for clotting complications. Other studies quantified the target population for tocilizumab treatment and gender differences in infections.
https://immattersacp.org/weekly/archives/2021/05/25/1.htm
25 May 2021
Many recent studies reporting on COVID-19 vaccines' safety, effectiveness
New studies looked at the safety of the adenovirus COVID-19 vaccines, the effectiveness of almost all the vaccines, and the impacts of COVID-19 infection in pregnancy and on long-term cardiac function. A physician columnist addressed pandemic-related anger.
https://immattersacp.org/weekly/archives/2021/05/11/1.htm
11 May 2021